Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Oncology InstituteTOI -3.95%56 EV-to-OCF is -25.69 as of Jul. 31, 2026. GuruFocus rates TOI with a GF Score™ of 56/100 and a GF Value™ of $2.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 683 Healthcare Providers & Services companies, The Oncology Institute ranks better than 91.22% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, The Oncology Institute's Enterprise Value is $560.5 Mil.
The Oncology Institute's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-21.8 Mil. Therefore, The Oncology Institute's EV-to-OCF for today is -25.69.
The historical rank and industry rank for The Oncology Institute's EV-to-OCF or its related term are showing as below:
TOI'
s EV-to-OCF Range Over the Past 10 Years
Min: -83.33 Med: -5.27 Max: -1.11
Current: -25.69
During the past 8 years, the highest EV-to-OCF of The Oncology Institute was -1.11. The lowest was -83.33. And the median was -5.27.
TOI's EV-to-OCF is ranked better than 91.22% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 8.65
vs TOI: -25.69
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The Oncology Institute (NAS:TOI) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The Oncology Institute's PE Ratio (TTM) for today is calculated as:
The Oncology Institute's share price for today is $4.86.
The Oncology Institute's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Oncology Institute's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's EV-to-OCF falls into.
The Oncology Institute's current Enterprise Value is $560.5 Mil.
The Oncology Institute's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOI) has a EV-to-OCF of -25.69 as of Jul. 31, 2026. According to the industry distribution chart, The Oncology Institute ranks #60 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 8.8%.
Is The Oncology Institute's EV-to-OCF too high?
The Oncology Institute's current EV-to-OCF is -25.69. Based on the distribution chart, The Oncology Institute ranks #60 out of 683 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, The Oncology Institute has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's EV-to-OCF compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #60 out of 683 companies for EV-to-OCF. This places The Oncology Institute in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 8.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.65, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current EV-to-OCF is -25.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
Based on GuruFocus' analysis, The Oncology Institute (TOI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.28, compared to a current price of $4.86 — trading 113.2% above its estimated fair value. The current EV-to-OCF is -25.69. The Oncology Institute's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For The Oncology Institute (TOI), the current EV-to-OCF is -25.69 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Oncology Institute (TOI) Overvalued in 2026?
Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued.
The current stock price of $4.86 is trading 113.2% above its estimated GF Value™ of $2.28.
GuruFocus considers The Oncology Institute to be Significantly Overvalued.
Key valuation signals for TOI:
EV-to-OCF: -25.69
GF Value™: $2.28 vs. price of $4.86 (113.2% above fair value)
No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOI
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOI has been successfully added to your 
